**Amendments to the Claims:**

This listing of claims will replace the version submitted on August 10, 2007.

1. (Currently amended) An activated compound having a formula:



(Formula 1)

wherein the activated compound is attached to the hydroxyl group and comprises an activating moiety selected from the group consisting of chloroformate, NHS carbonate, DSC para-nitrochloroformate, p-nitrochloroformate, phosgene and paranitrophenyl carbonate, and

where

$R^1$ is selected from the group consisting of alkyl, $-CH_2(OC_2H_4)OCH_3$, and $-(OC_2H_4)OCH_3$;

n is 0-4;

Olig is an oligomer having a formula:

where:

L is a optional linker moiety selected from the group consisting of $-CH_2O-$, $-CH_2OX-$, -OX-, -C(O)-, -C(O)X, -NH-, -NHC(O)-, -XNHC(O)-, -NHC(O)X, -C(O)NH-, -C(O)NHX-, and



,

where:

X is $alkyl_{1-6}$ or is not present,

Y is N or O or is not present, and

$R^3$ is $alkyl_{1-6}$;

PAG is a linear or branched polyalkylene glycol moiety;

$R^2$ is an $alkyl_{1-22}$ capping moiety if X is present or $alkyl_{2-22}$ if X is not present;

q is a number from 1 to the maximum number of branches on PAG; and

m is 1-5.

2. (Original) The compound of claim 1 comprising an Olig coupled to carbon 4 of the phenol moiety.

3. (Original) The compound of claim 1 comprising an Olig coupled to carbon 3 of the phenol moiety, and/or an Olig coupled to carbon 5 of the phenol moiety.

4. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 4 of the phenol moiety.

5. (Original) The compound of claim 1 wherein m is 1 and the Olig is coupled to carbon 3 or carbon 5 of the phenol moiety.

6. (Original) The compound of claim 1 wherein:
   (a) m is 2, and
   (b) a first Olig is coupled to carbon 3 of the phenol moiety, and
   (c) a second Olig is coupled to carbon 5 of the phenol moiety.

7. (Original) The compound of claim 1 wherein L is present and X is not present.

8. (Original) The compound of claim 1 wherein L and X are both present.

9. (Original) The compound of claim 1 wherein PAG is a linear polyalkylene glycol moiety.

10. (Original) The compound of claim 1 wherein PAG is a linear polyethylene glycol moiety.

11. (Original) The compound of claim 1 wherein PAG is a branched polyalkylene glycol moiety.

12. (Original) The compound of claim 1 wherein PAG is a branched polyethylene glycol moiety.

13. (Original) The compound of claim 1 wherein q is 1 to 5.

14. (Original) The compound of claim 1 wherein q is 2.

15. (Original) The compound of claim 1 wherein $R^2$ is alkyl $_{5-12}$.

16. (Original) The compound of claim 1 wherein $R^2$ is alkyl $_{1-4}$.

17. (Original) The compound of claim 1 wherein X is present and $R^2$ is methyl.

18. (Original) The compound of claim 1 wherein $R^1$ is alkyl$_{1-22}$.

19. (Original) The compound of claim 1 wherein $R^1$ is alkyl$_{1-12}$.

20. (Original) The compound of claim 1 wherein $R^1$ is alkyl$_{1-6}$.

21. (Original) The compound of claim 1 wherein $R^1$ is methyl and L is not amide or O.

22. (Original) The compound of claim 1 wherein $R^1$ is methyl.

23. (Cancelled)

24. (Cancelled)

25. (Previously presented) A biologically active agent comprising a compound of claim 1 covalently coupled thereto by a carbamate bond to form a prodrug which does or does not retain the biological activity of the biologically active agent, wherein the biologically active agent is a drug moiety or a protein drug moiety.

26. (Previously presented) A protein drug moiety covalently coupled to one or more of the compound of claim 1.

27. (Withdrawn) The compound of claim 1 having a formula:




(Formula 2),

wherein

X is not present;

PEG is linear or branched $PEG_{2-50}$;

L is not included;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

28. (Cancelled)

29. (Cancelled) :

30. (Withdrawn) The compound of claim 1 having a formula:




(Formula 5),

wherein

X is not present;

PEG is linear or branched $PEG_{2-50}$;

L is not included;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

31. (Withdrawn) The compound of claim 1 having a formula:




(Formula 6)

wherein

X is not present;

PEG is linear or branched $PEG_{2-50}$;

L is not included;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

32. (Withdrawn) The compound of claim 1 having a formula:




(Formula 7)

wherein

X is not present;

PEG is linear or branched $PEG_{2-50}$;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

33. (Withdrawn) The compound of claim 1 having a formula:




(Formula 8)

wherein

X is not present;

PEG is linear or branched $PEG_{2-50}$;

R is H or alkyl; and

n is a number from 1 to the maximum number of PEG branches.

34. (Withdrawn) The compound of claim 1 having a formula:




wherein

PEG is linear or branched PEG2-50;

R is H or alkyl;

m is 1 or 2; and

n is a number from 1 to the maximum number of PEG branches.

35. (Withdrawn) The compound of claim 34 wherein:

m is 2; and




s bound to the phenol moiety at positions 3 and 4.

36. (Previously presented) A compound having a formula:




wherein

X is an alkyl or is not present;

PEG is linear or branched $PEG_{2\text{-}50}$;

R is H or alkyl;

n is from 1 to the maximum number of PEG branches; and

$R^1$ is alkyl.

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (withdrawn) The compound of claim 1 having a formula:




(Compound 5).

42. (withdrawn) The compound of claim 1 having a formula:




(Compound 6).

43. (Previously presented) A compound having a formula:




(Compound 7).

44. (Original) The compound of claim 1, wherein the compound is a pure prodrug or partial prodrug.

45. (Original) A pharmaceutical composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.

46. (Cancelled)

47. (Previously presented) A method of treating a subject in need of treatment for diabetes comprising administering an effective amount of the compound of claim 1 that is conjugated to insulin to the subject.